Amitabh Parashar1,2, W Gregory Hundley3,4,5,6,7. 1. Section of Cardiology, Veterans Affairs Medical Center, Salem, VA, USA. 2. Virginia Tech Carilion School of Medicine, Roanoke, VA, USA. 3. Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, NC, USA. greg.hundley@vcuhealth.org. 4. Department of Radiological Sciences, Wake Forest School of Medicine, Winston-Salem, NC, USA. greg.hundley@vcuhealth.org. 5. Department of Internal Medicine, Virginia Commonwealth Health Sciences, Richmond, VA, USA. greg.hundley@vcuhealth.org. 6. Department of Radiological Sciences, Virginia Commonwealth Health Sciences, Richmond, VA, USA. greg.hundley@vcuhealth.org. 7. Department of Internal Medicine, Section on Cardiovascular Medicine, VCU Health Pauley Heart Center, Virginia Commonwealth University, Gateway bldg. 1200 E Marshall St, Richmond, VA, 23298, USA. greg.hundley@vcuhealth.org.
Abstract
PURPOSE OF REVIEW: Advancements in cancer treatment have resulted in improved cancer-related survival and consequently an increase in the number of cancer survivors. Unfortunately, associated with this increase in cancer-related survivorship, cardiac events have occurred with increasing frequency in cancer survivors. Recognition that cancer survivors are at increased risk for cardiovascular (CV) morbidity has generated interest to develop cardiac imaging techniques that identify subclinical CV disease during receipt of potentially cardiotoxic cancer treatment. Since subclinical cardiovascular disease precedes future cardiac events, early recognition of subclinical CV disease during receipt of potentially cardiotoxic cancer treatment offers the opportunity to initiate strategies that prevent further evolution of subclinical CV disease as well as cardiac events. RECENT FINDINGS: Cardiovascular magnetic resonance imaging (CMR) is an advanced imaging technique that identifies imaging markers of subclinical cardiovascular disease in patients receiving potentially cardiotoxic cancer treatment regimens. In this article, we review the use of CMR for identifying subclinical cardiac disease in patients receiving potentially cardiotoxic cancer treatment regimens. The ability of contemporary CMR to accurately define cardiac anatomy, function, and tissue characteristics may represent a critical tool to assess patients with cancer.
PURPOSE OF REVIEW: Advancements in cancer treatment have resulted in improved cancer-related survival and consequently an increase in the number of cancer survivors. Unfortunately, associated with this increase in cancer-related survivorship, cardiac events have occurred with increasing frequency in cancer survivors. Recognition that cancer survivors are at increased risk for cardiovascular (CV) morbidity has generated interest to develop cardiac imaging techniques that identify subclinical CV disease during receipt of potentially cardiotoxic cancer treatment. Since subclinical cardiovascular disease precedes future cardiac events, early recognition of subclinical CV disease during receipt of potentially cardiotoxic cancer treatment offers the opportunity to initiate strategies that prevent further evolution of subclinical CV disease as well as cardiac events. RECENT FINDINGS: Cardiovascular magnetic resonance imaging (CMR) is an advanced imaging technique that identifies imaging markers of subclinical cardiovascular disease in patients receiving potentially cardiotoxic cancer treatment regimens. In this article, we review the use of CMR for identifying subclinical cardiac disease in patients receiving potentially cardiotoxic cancer treatment regimens. The ability of contemporary CMR to accurately define cardiac anatomy, function, and tissue characteristics may represent a critical tool to assess patients with cancer.
Entities:
Keywords:
CardioOncology; Cardiovascular magnetic resonance
Authors: Gregory T Armstrong; Juan Carlos Plana; Nan Zhang; Deokumar Srivastava; Daniel M Green; Kirsten K Ness; F Daniel Donovan; Monika L Metzger; Alejandro Arevalo; Jean-Bernard Durand; Vijaya Joshi; Melissa M Hudson; Leslie L Robison; Scott D Flamm Journal: J Clin Oncol Date: 2012-07-16 Impact factor: 44.544
Authors: Nazanin Fallah-Rad; Jonathan R Walker; Anthony Wassef; Matthew Lytwyn; Sheena Bohonis; Tielan Fang; Ganhong Tian; Iain D C Kirkpatrick; Pawan K Singal; Marianne Krahn; Debjani Grenier; Davinder S Jassal Journal: J Am Coll Cardiol Date: 2011-05-31 Impact factor: 24.094
Authors: Jason N Dungu; Oswaldo Valencia; Jennifer H Pinney; Simon D J Gibbs; Dorota Rowczenio; Janet A Gilbertson; Helen J Lachmann; Ashutosh Wechalekar; Julian D Gillmore; Carol J Whelan; Philip N Hawkins; Lisa J Anderson Journal: JACC Cardiovasc Imaging Date: 2014-01-08
Authors: Tomas G Neilan; Otavio R Coelho-Filho; Diego Pena-Herrera; Ravi V Shah; Michael Jerosch-Herold; Sanjeev A Francis; Javid Moslehi; Raymond Y Kwong Journal: Am J Cardiol Date: 2012-08-21 Impact factor: 2.778
Authors: Sui Zhang; Xiaobing Liu; Tasneem Bawa-Khalfe; Long-Sheng Lu; Yi Lisa Lyu; Leroy F Liu; Edward T H Yeh Journal: Nat Med Date: 2012-10-28 Impact factor: 53.440
Authors: Louise Pyndt Diederichsen; Jane Angel Simonsen; Axel Cosmus Pyndt Diederichsen; Won Yong Kim; Svend Hvidsten; Mikkel Hougaard; Peter Junker; Ingrid E Lundberg; Henrik Petersen; Esben Søvsø Szocska Hansen; Karl Sannes Eskerud; Susan Due Kay; Søren Jacobsen Journal: Clin Exp Rheumatol Date: 2015-09-07 Impact factor: 4.473
Authors: Edith Pituskin; Mark Haykowsky; John R Mackey; Richard B Thompson; Justin Ezekowitz; Sheri Koshman; Gavin Oudit; Kelvin Chow; Joseph J Pagano; Ian Paterson Journal: BMC Cancer Date: 2011-07-27 Impact factor: 4.430